Literature DB >> 3111930

[Exclusive elemental enteral diet in cortico-resistant and cortico-dependent forms of Crohn's disease].

Y Le Quintrec, J Cosnes, M Le Quintrec, J F Contou, P Baumer, J Bellanger, J P Gendre.   

Abstract

The aim of this study was to investigate the value of elemental diet in steroid-resistant and steroid-dependent Crohn's disease. Elemental diet (Vivonex HN, 39.4 +/- 9.2 kcal/kg/d) was delivered through a nasogastric tube at a constant rate. Twenty therapeutic periods lasting from 20 to 74 days (median, 32 days) were undertaken in 18 patients. Elemental diet was well tolerated. Mean values of hemoglobin, serum albumin, and serum transferrin increased significantly through the therapeutic period; body weight and anthropometric data did not change significantly. The short-term response to elemental diet was excellent in 11 cases, demonstrated by achievement of clinical remission and steroid withdrawal; six patients had an incomplete remission and remained slightly active or had to be maintained under low dose steroids; three patients did not respond to therapy and had to be operated upon. During the follow-up (6-30 months), 8 patients out of 17 had a relapse. Relapse was controlled by medical therapy in 5 cases and led to surgery in the 3 other cases. We conclude that elemental diet, as total parenteral nutrition, is an effective therapy of steroid-resistant and steroid-dependent Crohn's disease. However, elemental diet does not prevent relapse.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111930

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  2 in total

1.  Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet.

Authors:  D Rigaud; J Cosnes; Y Le Quintrec; E René; J P Gendre; M Mignon
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 2.  Enteral nutrition in Crohn's disease: an underused therapy.

Authors:  S Kansal; J Wagner; C D Kirkwood; A G Catto-Smith
Journal:  Gastroenterol Res Pract       Date:  2013-12-05       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.